Adherence enhancing program for patients with metastatic, castration-resistant prostate carcinoma treated with abiraterone acetate plus prednisone: A cluster randomized trial.

Henrik Suttmann,Susan Feyerabend,Jochen Gleissner,Andreas Hübner,Tim Mathes,Werner Baurecht,Katrin Krützfeldt,Hussein Sweiti

Adherence enhancing program for patients with metastatic, castration-resistant prostate carcinoma treated with abiraterone acetate plus prednisone: A cluster randomized trial.

2019

Henrik Suttmann
Susan Feyerabend
Jochen Gleissner
Andreas Hübner
Tim Mathes
Werner Baurecht
Katrin Krützfeldt
Hussein Sweiti

e16520Background: Abiraterone acetate plus prednisone (AA+P) is an effective treatment for patients (pts) with metastatic, castration-resistant prostate carcinoma (mCRPC). Adherence is an important...

Keywords:

Abiraterone acetate
Cluster randomised controlled trial
Castration-Resistant Prostate Carcinoma
Urology
Pathology
Prednisone
Medicine
effective treatment
prostate carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations